personalized tumor neoantigen dendritic cells

Personalized tumor neoantigen dendritic cells are an autologous cell-based cancer vaccine developed by Peking University Shenzhen Hospital. The therapeutic process begins with identifying patient-specific somatic mutations (neoantigens) through next-generation sequencing (NGS) of the patient's tumor tissue and healthy cells. Synthetic peptides corresponding to these unique neoantigens are then used to pulse the patient's own monocyte-derived dendritic cells (DCs) in vitro. Once matured and activated, these DCs are re-infused into the patient, where they present the neoantigens to T cells, thereby inducing a potent and specific anti-tumor immune response. This approach is currently being investigated in Phase 1 clinical trials for the treatment of advanced colorectal cancer and other solid tumors, aiming to overcome the limitations of traditional vaccines by targeting mutations unique to each individual's cancer.

Other names

Personalized Neoantigen-pulsed Dendritic Cell VaccineNeoantigen-pulsed Dendritic Cell VaccinePersonalized Neoantigen DC Vaccine